| ●Editorial | Tsutani K | 441-2 |
| ●Information disclosure on clinical trials and international public health | ||
| Round table discussion：The intellectual properties on drugs in internattional health scene and the abolition of publication requirement of registration clinical trials in Japan |
'tHoen E, Nakajima H, Beppu H, et al. |
443-65 |
| 1，Intellectual property and public health | ||
| Prescrire editorial process [Japanese] & [English] | 467-74 | |
| Revised drug strategy [Japanese] & [English] | 475-81 | |
| Discussion on the WHO resolution on “Revised drug strategy” | Tsuda S | 483-6 |
| Public health first −Revised drug strategy addresses trade and health− | Sagoo K, Hayes L | 487-90 |
| 2，Current status and future of clinical trials registration | ||
| Report on attendance at the conference on “registering information about randomised controlled trials”, London, 1999 | Kaneko Y, Tsutani K | 491-501 |
| Finding out about unpublished trials through META −A challenge for evidence-based medicine− | Yanagawa T, Roberts I, Tsutani K | 503-8 |
| Being a modern pharmaceutical company −Involves making information available on clinical trial programmes− [Japanese] & [English] | Sykes R | 509-10 |
| How Glaxo Wellcome contributes to the avoidance of publication bias [Japanese] & [English] | Gibbs T | 511-7 |
| 3，Information disclosure through electronic media in Japan, the European
Union, and the United States | ||
| Transparency of the new drug review process and “New Drug Approval Package” by MHW, Japan | Narukawa M | 519-27 |
| Drug companies' intellectual property vs. public health | Mitsuishi T | 529-38 |
| Transparency and accountability in drug regulation −Dissemination of
information of clinical trials through electronic media by EMEA− | Bass R, Aronsson B | 539-44 |
| Transparency and accountability in drug regulation −Fighting for the right to know− | 'tHoen E | 545-53 |
| FDA Guidance for industry on disclosing information (Draft) | FDA/CDER | 555-61 |
| Dissemination of clinical trial information through the internet by FDA | Frost A | 563-7 |
| 4，Rational use of drug | ||
| The 2nd P-drug workshop in Japan −processing and planning− | Uchida E | 569-73 |
| The 2nd P-drug workshop held in Japan | Saio T | 575-8 |
| Managing Drug Selection −The 10 of “Managing Drug Supply” | Hogerzeil H (Matsumoto K, et al. trans.) | 579-98 |
| A note on the WHO Model Lists of Essential Drugs | Tsutani K | 599-600 |
| WHO Model List of Essential Drugs (11th list) | 601-14 | |
| ●Original | ||
| Effect of cilostazol, an antiplatelet agent on transient ischemic attack
(TIA) −A double-blind, randomized, controlled trial of cilostazol versus Aspirin− | Gotoh F, Tougi H, Hirai S, et al. | 615-43 |
| ●Instructions for authors [Japanese] & [English] | 645-50 | |
| ●Editor's note | Kawai S | 651 |